New combo aims to outsmart Drug-Resistant lung cancer

NCT ID NCT05845671

Ongoing Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, amivantamab, combined with standard targeted therapies (TKIs) in people with advanced non-small cell lung cancer that has specific gene changes (ALK, ROS1, or RET). The goal is to see if this combination can overcome drug resistance and shrink tumors. About 12 adults will take part to find the best dose and check how well it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma RET fusion positive cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

City of Hope Cancer Center

Duarte, California, 91010, United States
Outpatient CTRC

Aurora, Colorado, 80045, United States
University of Colorado Hospital

Aurora, Colorado, 80045, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.